Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
Baljinder Singh, Amrita Sharma, Gunaganti Naresh, Mitch Rivers, Pradip K. Gadekar, Brady Greene, Michael Chichioco, Carlos E. Sanz-Rodríguez, Courtney Fu, Catherine Leblanc, Erin Burchfield, Nyle Sharif, Benjamin U. Hoffman, Gaurav Kumar, Andrei A. Purmal, Kojo Mensa‐Wilmot, Michael P. Pollastri
Abstract
High Resolution Image Download MS PowerPoint Slide The carbazole CBL0137 ( 1 ) is a lead for drug development against human African trypanosomiasis (HAT), a disease caused by Trypanosoma brucei . To advance 1 as a candidate drug, we synthesized new analogs that were evaluated for the physicochemical properties, antitrypanosome potency, selectivity against human cells, metabolism in microsomes or hepatocytes, and efflux ratios. Structure–activity/property analyses of analogs revealed eight new compounds with higher or equivalent selectivity indices ( 5j, 5t, 5v, 5w, 5y, 8d, 13i, and 22e ). Based on the overall compound profiles, compounds 5v and 5w were selected for assessment in a mouse model of HAT; while 5v demonstrated a lead-like profile for HAT drug development, 5w showed a lack of efficacy. Lessons from these studies will inform further optimization of carbazoles for HAT and other indications.